2018
428P Interim results from a phase I trial of SL-801: A novel XPO-1 inhibitor, in patients with advanced solid tumors
Bauer T, Barve M, Chiorean E, Lorusso P, Courtney K, Qi D, Olguin A, Bullington J, Sardone M, Dunn V, Shemesh S, Chen J, Brooks C, Wang J. 428P Interim results from a phase I trial of SL-801: A novel XPO-1 inhibitor, in patients with advanced solid tumors. Annals Of Oncology 2018, 29: viii140. DOI: 10.1093/annonc/mdy279.415.Peer-Reviewed Original ResearchPreliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors.
Sanborn R, Menke C, Autio K, Arkenau H, Corbacho J, LoRusso P, Plummer E, Uboha N, Freeman M, Wydmanski J, Huels V, Zheng B, Will M, Humphrey R, Thistlethwaite F, de Vries E, El-Khoueiry A. Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2018, 36: 3072-3072. DOI: 10.1200/jco.2018.36.15_suppl.3072.Peer-Reviewed Original Research
2017
406P Ongoing phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors; Interim results
Wang J, Nemunaitis J, Chiorean G, Lorusso P, Courtney K, Olguin A, Bullington J, Shemesh S, Chen J, Brooks C, Bauer T. 406P Ongoing phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors; Interim results. Annals Of Oncology 2017, 28: v135. DOI: 10.1093/annonc/mdx367.039.Peer-Reviewed Original Research